Does systemic treatment of psoriasis reduce the risk of comorbidities?
- PMID: 31495927
- DOI: 10.1111/bjd.18456
Does systemic treatment of psoriasis reduce the risk of comorbidities?
Comment on
-
Management of psoriasis as a systemic disease: what is the evidence?Br J Dermatol. 2020 Apr;182(4):840-848. doi: 10.1111/bjd.18245. Epub 2019 Oct 15. Br J Dermatol. 2020. PMID: 31225638 Free PMC article. Review.
References
-
- Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol 2020; 182:840-48.
-
- Lu Y, Chen H, Nikamo P et al. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol 2013; 133:836-9.
-
- Budu-Aggrey A, Brumpton B, Tyrrell J et al. Evidence of a causal relationship between body mass index and psoriasis: a mendelian randomization study. PLOS Med 2019; 16:e1002739.
-
- Furue M, Tsuji G, Chiba T, Kadono T. Cardiovascular and metabolic diseases comorbid with psoriasis: beyond the skin. Intern Med 2017; 56:1613-19.
-
- Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol 2018; 79:345-52.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical